

GUFIC BIOSCIENCES LIMITED					
Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069 (CIN- L24100MH1984PLC033519) Website - www.gufic.com, email - info@guficbio.com, Ph-022 67261000, Fax - 022 67261068 (Rs. in Lakhs except EPS)					
Statement of Unaudited Financial Results for the Quarter Ended June 30, 2022					
Sr. No.	Particulars	Quarter Ended			Year ended
		30-Jun-22	30-Jun-21	31-Mar-22	31-Mar-22
		Unaudited	Unaudited	Audited	Audited
1	INCOME				
a	Revenue from operations	16,527.63	25,075.77	16,219.31	77,915.56
b	Other income	37.47	122.82	4.07	310.42
	Total Income	16,565.10	25,198.59	16,223.38	78,225.98
2	Expenses				
a	Cost of materials consumed	6,311.38	11,261.58	7,732.65	35,393.40
b	Purchase of stock-in-trade	677.05	3,544.11	1,218.54	7,741.84
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	764.73	(28.47)	(1,803.43)	(1,938.86)
d	Employee benefits expense	2,142.73	2,547.86	1,930.99	8,561.18
e	Finance cost	90.83	120.94	105.65	484.68
f	Depreciation and amortisation expense	436.50	412.58	432.71	1,713.38
g	Other expenses	3,313.85	3,185.88	3,988.64	13,586.53
	Total Expenses	13,737.07	21,044.48	13,605.75	65,542.15
3	Total Profit before exceptional items and tax (1-2)	2,828.03	4154.11	2,617.63	12,683.83
4	Exceptional items				
5	Total Profit Before Tax	2,828.03	4154.11	2,617.63	12,683.83
6	Tax expense				
	Current tax	736.00	1,056.00	665.00	3,215.00
	Deferred tax	(13.12)	(22.59)	(73.79)	(115.18)
	Short/(Excess) tax provision of earlier years	-	-	-	-
	Total Tax Expenses	722.88	1033.41	591.21	3,099.82
7	Net Profit for the period from continuing operations	2,105.15	3120.70	2,026.42	9,584.01
8	Total Profit for period	2,105.15	3120.70	2,026.42	9,584.01
9	Other Comprehensive Income (OCI)				
	Items that will not be reclassified to Profit/(Loss)	-	-	(58.88)	(58.88)
	Less: Income tax relating to items that will not be reclassified to Profit/(Loss)	-	-	14.82	14.82
	Other Comprehensive Income/(Loss) (net of taxes)	-	-	(44.06)	(44.06)
10	Total Comprehensive Income	2,105.15	3120.70	1,982.36	9,539.95
11	Reserves				25,942.35
12	Details of Equity Share Capital				
	Paid-up equity share capital	969.45	969.45	969.45	969.45
	Face Value of equity share capital (Rs.)	1.00	1.00	1.00	1.00
13	Earning per equity share				
i	Basic earnings per share from continuing and discontinued operations	2.17	3.22	2.09	9.89
ii	Diluted earnings per share from continuing and discontinued operations	2.17	3.22	2.09	9.89



Notes:

- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
- The above results for the quarter ended June 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 11, 2022. The Statutory Auditors have carried out audit of the results for quarter ended June 30, 2022.
- The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
- The figures for the quarter ended March 31st, 2022 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31st, 2021, which were subjected to limited review.
- Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED

PRANAV J. CHOKSI
CEO & WHOLE TIME DIRECTOR
DIN : 00001731

PLACE : MUMBAI
DATE : 11/08/2022





MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

Limited Review Report on the Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended 30 June 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)




Piyush Agarwal
Partner

Membership No. 135505

Place: Mumbai
Dated: 11/08/2022
UDIN: 22135505A0VUMS6420